WHO/HIV/2013.12
© World Health Organization 2013
Title: Initiation of ART at CD4 count >350 cells/mm3 compared to <350 cells/mm3 among people coinfected with HIV and hepatitis B virus (HBV) Contents 1. 2. PICO question ....................................................................................................................................... 1 Search strategy ...................................................................................................................................... 1
NO STUDIES WERE FOUND FOR THIS QUESTION
1. PICO question HBV and HCV combined PICO question
P I C O
When to start ART: HIV and hepatitis B and C coinfection 1) People with HIV and HCV infection 2) People with HIV and HBV infection ART initiation at CD4 >350 cells/mm3 or irrespective of CD4 cell count Defer ART initiation until CD4 cell count ≤350 cells/mm3 or symptomatic HIV disease (WHO stages 3 and 4) HIV mortality and morbidity, non-HIV mortality and morbidity, response to HCV therapy (for HIV and HCV coinfection), HBV transmission (for HIV and HBV coinfection), severe adverse events, adherence, retention, HIV drugresistance, TB incidence
2. Search strategy HBV and HCV combined search strategy 01 Jan 1996 – 2 Aug 2012 Search #6 #5 Query Search ((((#1) AND #2) AND #3) AND #4) AND #5 Search HAART[tiab] OR ART[tiab] OR antiretroviral[tiab] OR anti-retroviral[tiab] OR "Anti-HIV Agents/therapeutic use"[MeSH] OR "Drug Therapy, Combination/methods"[MeSH] OR Antiretroviral Therapy, Highly Active[MeSH] Search randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [MeSH] OR random allocation [MeSH] OR double-blind method [MeSH] OR single-blind method [MeSH] OR clinical trial [pt] OR clinical trials [MeSH] OR ("clinical trial" [tiab]) OR ((singl* [tiab] OR doubl* [tiab] OR trebl* [tiab] OR tripl* [tiab]) AND (mask* [tiab] OR blind* [tiab])) OR (placebos [MeSH] OR placebo* [tiab] OR random* [tiab] OR research design [mh:noexp] OR follow-up studies [MeSH] OR prospective studies [MeSH] OR control*[tiab] OR prospectiv* [tiab]) OR nonrandomi*[tiab] OR before after study[tiab] OR time series[tiab] OR case control[tiab] OR prospective cohort[tiab] OR cohort*[tiab] OR cross-section*[tiab] OR prospective[tiab] OR retrospective[tiab] OR research design[mh:noexp] OR follow-up studies[MeSH] OR prospective studies[MeSH] OR control*[tiab] OR prospectiv*[tiab]) NOT (animals [MeSH] NOT human [MeSH]) Search (start*[tiab] OR initia*[tiab] OR begin*[tiab] OR timing[tiab] OR early[tiab] OR
#4
#3
This work was commissioned by the World Health Organization and carried out by The University of California, San Francisco (UCSF), Cochrane Review Group on HIV/AIDS
1
WHO/HIV/2013.12
© World Health Organization 2013
Search
#2 #1
Query earli*[tiab] OR (CD4[tiab] AND (irrespective[tiab] OR “above 350”[tiab] OR ≥350[tiab] OR >350[tiab])) Search "Hepatitis, Viral, Human"[Mesh] OR "viral hepatitis"[tiab] OR "hepatitis B"[tiab] OR HBV[tiab] OR "hepatitis C"[tiab] OR HCV[tiab] Search HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immuno-deficiency virus[tiab] OR human immunedeficiency virus[tiab] OR ((human immun*) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno-deficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR ((acquired immun*) AND (deficiency syndrome[tiab]))
This work was commissioned by the World Health Organization and carried out by The University of California, San Francisco (UCSF), Cochrane Review Group on HIV/AIDS
2